Drugs Information: Cemiplimab
Basic Information
|
||
| ID | DDInter337 | |
| Drug Type | biotech | |
| Molecular Formula | None | |
| Molecular Weight | - | |
| Description | The U.S. Food and Drug Administration (FDA) approved Cemiplimab (_Libtayo_), manufactured by Regeneron Pharmaceuticals, on September 28, 2018. This is the first FDA approval of a drug specifically for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) [A39201, L4615]. | |
| ATC Classification | L01XC33 | |
| IUPAC Name | None | |
| InChI | None | |
| InChI Key | None | |
| Canonical SMILES | None | |
| Useful Links | DrugBank | |
Interactions with Cemiplimab
| Severity level | ID | Name | Mechanism | Detail |
|---|